DK1481687T3 - Anvendelse af multimere ligander af TNF-familien med reduceret toksicitet til behandling af celleprofilferative sygdomme - Google Patents
Anvendelse af multimere ligander af TNF-familien med reduceret toksicitet til behandling af celleprofilferative sygdommeInfo
- Publication number
- DK1481687T3 DK1481687T3 DK04356079T DK04356079T DK1481687T3 DK 1481687 T3 DK1481687 T3 DK 1481687T3 DK 04356079 T DK04356079 T DK 04356079T DK 04356079 T DK04356079 T DK 04356079T DK 1481687 T3 DK1481687 T3 DK 1481687T3
- Authority
- DK
- Denmark
- Prior art keywords
- tnf
- rtm
- ligand
- superfamily member
- mice
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 6
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000000069 prophylactic effect Effects 0.000 title 1
- 231100000331 toxic Toxicity 0.000 title 1
- 230000002588 toxic effect Effects 0.000 title 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 6
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 6
- 241000699670 Mus sp. Species 0.000 abstract 3
- 238000002347 injection Methods 0.000 abstract 3
- 239000007924 injection Substances 0.000 abstract 3
- 230000000052 comparative effect Effects 0.000 abstract 2
- 108010029697 CD40 Ligand Proteins 0.000 abstract 1
- 102100032937 CD40 ligand Human genes 0.000 abstract 1
- 108010039471 Fas Ligand Protein Proteins 0.000 abstract 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20030291247 EP1481686A1 (fr) | 2003-05-26 | 2003-05-26 | Utilisation de multimères de ligands de la famille du TNF à toxicité réduite dans le traitement de maladies prolifératives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1481687T3 true DK1481687T3 (da) | 2007-12-27 |
Family
ID=33104204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04356079T DK1481687T3 (da) | 2003-05-26 | 2004-05-25 | Anvendelse af multimere ligander af TNF-familien med reduceret toksicitet til behandling af celleprofilferative sygdomme |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP1481686A1 (fr) |
| JP (2) | JP4698973B2 (fr) |
| AT (1) | ATE369872T1 (fr) |
| CY (1) | CY1106986T1 (fr) |
| DE (1) | DE602004008146T2 (fr) |
| DK (1) | DK1481687T3 (fr) |
| ES (1) | ES2291838T3 (fr) |
| PL (1) | PL1481687T3 (fr) |
| PT (1) | PT1481687E (fr) |
| SI (1) | SI1481687T1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7884953B1 (en) | 2000-06-02 | 2011-02-08 | Mars Incorporated | High resolution ink-jet printing on edibles and products made |
| EP1481686A1 (fr) * | 2003-05-26 | 2004-12-01 | Apoxis SA | Utilisation de multimères de ligands de la famille du TNF à toxicité réduite dans le traitement de maladies prolifératives |
| WO2005058351A2 (fr) * | 2003-12-17 | 2005-06-30 | Entelos, Inc. | Traitement de la polyarthrite rhumatoide a l'aide d'agents de reticulation de ligand fas soluble |
| WO2006077232A2 (fr) * | 2005-01-20 | 2006-07-27 | Apoxis Sa | Ligand fas soluble multimerique destine a l'elimination de lymphocytes t alloreactifs lors de la transplantation de cellules souches hematopoietiques allogeniques |
| WO2019058263A1 (fr) * | 2017-09-19 | 2019-03-28 | Auckland Uniservices Limited | Peptides pour le traitement d'états associés à un dysfonctionnement de l'adiponectine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19963859A1 (de) * | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| EP1481686A1 (fr) * | 2003-05-26 | 2004-12-01 | Apoxis SA | Utilisation de multimères de ligands de la famille du TNF à toxicité réduite dans le traitement de maladies prolifératives |
-
2003
- 2003-05-26 EP EP20030291247 patent/EP1481686A1/fr not_active Withdrawn
-
2004
- 2004-05-25 AT AT04356079T patent/ATE369872T1/de active
- 2004-05-25 DE DE602004008146T patent/DE602004008146T2/de not_active Expired - Lifetime
- 2004-05-25 PT PT04356079T patent/PT1481687E/pt unknown
- 2004-05-25 PL PL04356079T patent/PL1481687T3/pl unknown
- 2004-05-25 DK DK04356079T patent/DK1481687T3/da active
- 2004-05-25 SI SI200430426T patent/SI1481687T1/sl unknown
- 2004-05-25 ES ES04356079T patent/ES2291838T3/es not_active Expired - Lifetime
- 2004-05-25 EP EP04356079A patent/EP1481687B1/fr not_active Expired - Lifetime
- 2004-05-26 JP JP2004156432A patent/JP4698973B2/ja not_active Expired - Fee Related
-
2007
- 2007-11-08 CY CY20071101437T patent/CY1106986T1/el unknown
-
2011
- 2011-01-20 JP JP2011010153A patent/JP2011102322A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP4698973B2 (ja) | 2011-06-08 |
| JP2004352717A (ja) | 2004-12-16 |
| EP1481686A1 (fr) | 2004-12-01 |
| JP2011102322A (ja) | 2011-05-26 |
| SI1481687T1 (sl) | 2007-12-31 |
| EP1481687A1 (fr) | 2004-12-01 |
| DE602004008146D1 (de) | 2007-09-27 |
| CY1106986T1 (el) | 2012-09-26 |
| PT1481687E (pt) | 2007-10-16 |
| ATE369872T1 (de) | 2007-09-15 |
| EP1481687B1 (fr) | 2007-08-15 |
| DE602004008146T2 (de) | 2008-05-29 |
| PL1481687T3 (pl) | 2008-01-31 |
| ES2291838T3 (es) | 2008-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6654670B2 (ja) | 幹細胞の免疫制御作用を調節する方法 | |
| Faunce et al. | Acute ethanol exposure prior to thermal injury results in decreased T-cell responses mediated in part by increased production of IL-6 | |
| US12156889B2 (en) | Methods of administering mesenchymal stem cells activated by cytokines for enhancing immunosuppression | |
| Wang et al. | Interleukin-10-overexpressing mesenchymal stromal cells induce a series of regulatory effects in the inflammatory system and promote the survival of endotoxin-induced acute lung injury in mice model | |
| CY1106986T1 (el) | Χρηση πολυμερικων συνδετων της tnf οικογενειας με μειωνενη τοξικοτητα για αντιμετωπιση νοσων του κυτταρικου πολλαπλασιασμου | |
| EP3307285A1 (fr) | Composition et procédé permettant d'induire l'anti-apoptose, la survie ou la prolifération de cellule | |
| Nardini et al. | CpG‐oligodeoxynucleotides induce mobilization of hematopoietic progenitor cells into peripheral blood in association with mouse KC (IL‐8) production | |
| MX2007016060A (es) | Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa. | |
| Kim et al. | Soluble triggering receptor expressed on myeloid cells-1 as a new therapeutic molecule in rheumatoid arthritis | |
| Islam et al. | Biological activities of sinularin: A literature-based review | |
| IL138024A (en) | Pharmaceuticals containing heparin to inhibit TNF activity | |
| CN104784680B (zh) | λ干扰素在制备抗汉滩病毒药物中的应用 | |
| CN118403061B (zh) | 胆汁酸衍生物在制备预防和治疗肝脏缺血再灌注损伤药物中的应用 | |
| Talal et al. | Evaluation of Liver And Plasma HCV RNA Kinetics And Telaprevir Levels In Genotype 1 HCV Patients Treated With Telaprevir (TVR) Using Serial Fine Needle Aspirates (FNA): 215 | |
| Bonnafous et al. | IPH1101 FIRST GENERATION γδT CELL AGONIST. EX VIVO AND IN VIVO ANTIVIRAL FUNCTIONS OF γδT CELLS FROM CHRONICALLY INFECTED HCV PATIENTS TREATED IN PHASE 2 STUDY: 1583 | |
| Chen et al. | Suppression of elevated plasma interleukin-8 levels due to total ischemia and reperfusion of the small intestine by luminal perfusion with fetal bovine serum | |
| Iyer et al. | Proposed Stem Cell Therapies for Infectious Diseases Including COVID-19 | |
| Du et al. | PATHOGENESIS OF BRAIN EDEMA IN ACUTE LIVER FAILURE: KEY ROLE OF THE ASTROCYTIC GLUTAMINE TRANSPORTER SNAT-3: 1598 | |
| Pinson et al. | 56 DYNAMICS OF HCV QUASISPECIES DURING TELAPREVIR TREATMENT DISSECTED USING ULTRA-DEEP PYROSEQUENCING: TREATMENT FAILURE IN 100% OF GENOTYPE 1A PATIENTS | |
| Novelli et al. | Adacolumn treatment in kidney transplant patients with hepatitis C virus | |
| Inoue et al. | NON-IMMUNOSUPPRESSIVE CYCLOSPORIN DEBIO-025 WITH INTERFERON SHOWS SYNERGISTIC ANTI-HCV EFFECT IN CHIMERIC MOUSE: 132 | |
| Parker et al. | NANOPARTICLE DELIVERY OF siRNA GENE KNOCKDOWN TO REDUCE PRO-INFLAMMATORY GENE EXPRESSION IN THE DONOR KIDNEY. | |
| McSharry et al. | Use of the BelloCell System to Determine the Optimal Dose of Ribavirin to Inhibit the Expression of an HCV Replicon in 2209-23 Cells | |
| Dallas et al. | 57 MINIMAL-LENGTH SHRNAS ARE POTENT INHIBITORS OF HEPATITIS C VIRUS IN HCV-INFECTED CHIMERIC MICE | |
| Nakamura et al. | ENDOTHELIAL PROGENITOR CELL TRANSPLANTATION AMELIORATES ESTABLISHED LIVER FIBROSIS AND DYSFUNCTION IN LIVER CIRRHOTIC MODEL RATS: 133 |